TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04700657

Intervention type: DIAGNOSTIC_TEST
Intervention: corneal sensation test
Description: Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group

Intervention type: DIAGNOSTIC_TEST
Intervention: corneal sensation test
Description: Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
Study: NCT03723811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP002 BID
Description: 1 drop b.i.d for 12 weeks
Study: NCT03823352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Study: NCT01585428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
Study: NCT03723811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP002 QID
Description: 1 drop q.i.d for 12 weeks
Study: NCT01585428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study: NCT01084174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut powder
Description: Delivered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut extract
Description: Delivered sublingually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo extract
Description: Delivered sublingually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: Delivered orally
Study: NCT00607529

Intervention type: OTHER
Intervention: hand-held POC creatinine analyzer-blood test
Description: This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis.
Study: NCT01879501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Self-Management Program
Description: The program has been describe above.
Study: NCT00869206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study: NCT03578289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health - CBT
Description: The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health - CBT
Description: The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
Study: NCT01594125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib high dose
Description: twice daily oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib low dose
Description: twice daily oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib medium dose
Description: twice daily oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib medium dose
Description: twice daily oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib high dose
Description: twice daily oral dosing
Study: NCT01404390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6946
Description: 0.4mg/ kg, iv, day 1,8 and 15, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6946
Description: 0.8mg/ kg, iv, day 1,8 and 15, every 28 days
Study: NCT00503009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol
Description: comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT04688307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
Study: NCT03327298

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pedicle screw fixation
Description: One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
Study: NCT03502226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored feedback
Description: Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing.
Study: NCT03103386

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intake of food product with a patented fermented rye bran
Description: During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: intake of food product with common refined wheat
Description: During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
Study: NCT02150096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous ultrasound group
Description: the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous ultrasound group
Description: the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulsed ultrasound group
Description: the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulsed ultrasound group
Description: the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy group
Description: the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy group
Description: the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
Study: NCT01197053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epicutaneous Immunotherapy
Description: 100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo of peanut
Description: placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
Study: NCT03274414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Proton Radiotherapy
Description: Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Resection
Description: In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and etoposide
Description: If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
Study: NCT04379089

Intervention type: OTHER
Intervention: Observational study only
Description: No Intervention
Study: NCT00022633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02054416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArtAssist© Device
Description: The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ArtAssist© Device
Description: The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
Study: NCT01012856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Depression
Description: 22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-Based Cognitive Therapy for Depression
Description: 22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
Study: NCT05868863

Intervention type: OTHER
Intervention: datas of medical record.
Description: Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking
Study: NCT03549871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPA prophylaxis
Description: Pharmaceutical form: solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor (FVIII or FIX) prophylaxis
Description: Pharmaceutical form: solution for injection Route of administration: Intravenous
Study: NCT02682589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
Study: NCT03723811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SJP002 Placebo 1
Description: 1 drop q.i.d for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SJP002 Placebo 2
Description: 1 drop q.i.d for 12 weeks
Study: NCT01569178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow aspiration and intracoronary reinfusion
Description: Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
Study: NCT04593563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
Study: NCT01643655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs Transplantation
Description: Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
Study: NCT00703079

Intervention type: DRUG
Intervention: Octreotide-LAR or lanreotide
Description: Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels

Intervention type: DRUG
Intervention: Octreotide-LAR or lanreotide
Description: Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels

Intervention type: DRUG
Intervention: Octreotide-LAR or lanreotide
Description: Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels

Intervention type: PROCEDURE
Intervention: Transsphenoidal adenomectomy
Description: Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.

Intervention type: PROCEDURE
Intervention: Transsphenoidal adenomectomy
Description: Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
Study: NCT04317430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: lactose tablets
Study: NCT02106884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study: NCT00703079

Intervention type: PROCEDURE
Intervention: Transsphenoidal adenomectomy
Description: Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
Study: NCT01607086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cherry lamotrigine ODT
Description: 25mg, taken orally on one study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cherry lamotrigine ODT
Description: 25mg, taken orally on one study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cherry Placebo
Description: Taken orally on one study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cherry Placebo
Description: Taken orally on one study visit
Study: NCT03913793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise based-cardiac rehabilitation (EB-CR) program
Description: The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise based-cardiac rehabilitation (EB-CR) program
Description: The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
Study: NCT01265173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: 3 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: 2 g
Study: NCT01690247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional plus UC-MSC
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional plus placebo
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Study: NCT03468257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pavlovian Conditioning
Description: Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pavlovian Conditioning
Description: Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
Study: NCT03886350

Intervention type: OTHER
Intervention: blood and sputum samples
Description: Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
Study: NCT03966703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mixing analysing test
Description: The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mixing analysing test
Description: The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
Study: NCT00789451

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
Study: NCT02682589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: 3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
Study: NCT00964340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
Study: NCT01265173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 400 mg
Study: NCT04101227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD04 (ondansetron)
Description: AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Companion Diagnostic for Genetic Testing
Description: Companion Diagnostic for Genetic Testing